Dr. Moore is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3100 Plaza Properties Blvd
Columbus, OH 43219Phone+1 614-383-6000Fax+1 614-383-6001
Education & Training
- Ohio State University HospitalFellowship, Hematology and Medical Oncology, 1985 - 1988
- UPMC Medical Education/MercyResidency, Internal Medicine, 1982 - 1985
- University of Cincinnati Medical Center/College of MedicineInternship, Internal Medicine, 1981 - 1982
- University of Pittsburgh School of MedicineClass of 1981
- Allegheny CollegeB.S., 1977
Certifications & Licensure
- OH State Medical License 1994 - 2026
- MD State Medical License 1988 - 1995
- WV State Medical License 1991 - 1993
- PA State Medical License 1983 - 1992
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Hospice and Palliative Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer Start of enrollment: 2019 Jul 25
- Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Start of enrollment: 2019 Feb 07
- Join now to see all
Publications & Presentations
PubMed
- 84 citationsEmerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy.Sindhu Ramesh, Manoj Govindarajulu, Rachel S. Parise, Logan Neel, Tharanath Shankar
Vaccines. 2021-10-18 - 217 citationsNSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by...Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer, Priya Rastogi, Joseph P. Costantino
Journal of Clinical Oncology. 2020-02-10 - 60 citationsEffect of nitric oxide and cyclooxygenase products on vascular resistance in dog and rat lungsJ. W. Barnard, P. S. Wilson, Timothy Moore, W. J. Thompson, Aubrey E. Taylor
Journal of Applied Physiology. 1993-06-01
Journal Articles
- Thomas JP, Moore T, Kraut EH, Balcerzak SP, Galloway S, Vandre DD, Clin Breast Cancer, 6/1/2006
- Philip Kuebler J, Moore T, Pritchard J, Kraut E, Invest New Drugs., 4/1/2004
- Laufman LR, Spiridonidis CH, Pritchard J, Roach R, Zangmeister J, Larrimer N, Moore T, Segal M, Jones J, Patel T, Gutterman L, Carman L, Colborn D, Kuebler JP, Ann Oncol., 9/1/2001
- Join now to see all
Books/Book Chapters
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: